🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

PET/MR for Characterization of Renal Masses (RMs)

Recruitingn/aAges 18 Years - anyAllUniversity of Texas Southwestern Medical Center
NCT06076538 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The frequency of kidney tumors found incidentally on imaging studies performed for unrelated reasons continues to increase leading to more surgeries and ablations for the treatment of renal masses thought to be cancer. However, about 20% of these masses are not cancerous and do not require treatment. Many cancerous kidney tumors are indolent and can be followed safely with imaging (i.e., particularly tumors \<2 cm and in patients with limited life expectancy), while some tumors are both malignant and aggressive, with a higher potential to spread outside the kidney and require treatment. The purpose of this observational study is to assess the ability of Fludeoxyglucose (18F) (FDG) PET/MR to distinguish different types of kidney tumors. The investigators hypothesize that PET/MR will better show differences between aggressive and both indolent and benign kidney masses compared to the curr

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with known solid (\>25% total volume enhances) renal mass * Renal mass size measuring \>2 to ≤7 cm * Age \>18 years * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Pregnancy * Prior percutaneous biopsy of the renal mass * Prior treatment of the renal mass * Prior hemorrhage in the renal mass * Contraindication to MRI or PET * Renal mass not eligible for ccLS based on prior imaging (i.e., containing macroscopic fat \[classic angiomyolipoma\] or enhancing less than 25% of its volume \[considered a cystic renal mass\]) * Genetic syndrome predisposing to renal masses (e.g., VHL, BHD, TSC, etc.); * More than 3 renal masses at time of initial diagnosis
💊

What it tests

  • 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
📍

Where

2 sites
University of Texas Southwestern Medical Center
Dallas, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy